English Polski
Vol 34, No 62 (2024): Continuous Publishing
Case report
Published online: 2024-11-06

open access

Page views 104
Article views/downloads 51
Get Citation

Connect on Social Media

Connect on Social Media

Progressive epileptic encephalopathy due to mutations in the HSD17B gene — bifunctional enzyme deficiency. A case report

Sylwia Maria Pawlak-Kurek1, Łukasz Przysło1
Neurol Dziec 2024;34(62):11-17.

Abstract

Peroxisomal diseases result from genetically determined abnormal production of peroxisomes or a deficiency of a single peroxisomal enzyme. They are characterized by a wide, partially overlapping spectrum of symptoms, and in standard clinical assessment their molecular basis is impossible to differentiate. The most severe form of peroxisome biogenesis disorders is Zellweger syndrome, associated with a characteristic phenotype and key symptoms: hypotension, the onset of seizures at 1 month of life, neurodevelopmental delay, and increased VLCFA concentration in the serum. A similar clinical picture is observed in bifunctional protein deficiency, hence it is sometimes called pseudo-Zellweger syndrome. The following paper presents a case of a patient with a bifunctional enzyme deficiency. There is no causal treatment for peroxisomal diseases and treatment is only supportive and symptomatic.

Article available in PDF format

View PDF (Polish) Download PDF file

References

  1. Zschocke J, Hoffmann G. Vademecum Metabolicum. Milupa Gmbh, Friedrichsdorf 2004.
  2. Stradomska TJ. Peroxisomal disorders. Postepy Biochem. 2018; 64(4): 359–367.
  3. Möller G, van Grunsven EG, Wanders RJ, et al. Molecular basis of D-bifunctional protein deficiency. Mol Cell Endocrinol. 2001; 171(1-2): 61–70.
  4. Orpha.net. Zaburzenia biogenezy peroksysomów, spektrum zespołu Zellwegera. https://www.orpha.net/pdfs/data/patho/PL/ZaburzeniabiogenezyperoksysomuspektrumzespoluZellwegera-PLplAbs11215.pdf.
  5. Klouwer FCC, Berendse K, Ferdinandusse S, et al. Zellweger spectrum disorders: clinical overview and management approach. Orphanet J Rare Dis. 2015; 10: 151.
  6. Steinberg SJ, Raymond GV, Braverman NE, et al. Zellweger Spectrum Disorder. GeneReviews® [Internet].
  7. Braverman NE, D'Agostino MD, Maclean GE. Peroxisome biogenesis disorders: Biological, clinical and pathophysiological perspectives. Dev Disabil Res Rev. 2013; 17(3): 187–196.
  8. Lee PR, Raymond GV. Child neurology: Zellweger syndrome. Neurology. 2013; 80(20): e207–e210.
  9. Ferdinandusse S, Denis S, Mooyer PAW, et al. Clinical and biochemical spectrum of D-bifunctional protein deficiency. Ann Neurol. 2006; 59(1): 92–104.
  10. Landau YE, Heimer G, Barel O, et al. Four patients with D-bifunctional protein (DBP) deficiency: expanding the phenotypic spectrum of a highly variable disease. Mol Genet Metab Rep. 2020; 25: 100631.
  11. Amor DJ, Marsh APL, Storey E, et al. Heterozygous mutations in cause juvenile peroxisomal D-bifunctional protein deficiency. Neurol Genet. 2016; 2(6): e114.
  12. Nascimento J, Mota C, Lacerda L, et al. D-bifunctional protein deficiency: a cause of neonatal onset seizures and hypotonia. Pediatr Neurol. 2015; 52(5): 539–543.
  13. McMillan HJ, Worthylake T, Schwartzentruber J, et al. Specific combination of compound heterozygous mutations in 17β-hydroxysteroid dehydrogenase type 4 (HSD17B4) defines a new subtype of D-bifunctional protein deficiency. Orphanet Journal of Rare Diseases. 2012; 7(1).
  14. Grønborg S, Krätzner R, Spiegler J, et al. Typical cMRI pattern as diagnostic clue for D-bifunctional protein deficiency without apparent biochemical abnormalities in plasma. Am J Med Genet A. 2010; 152A(11): 2845–2849.
  15. Wanders RJA, Waterham HR. Peroxisomal disorders: The single peroxisomal enzyme deficiencies. Biochim Biophys Acta. 2006; 1763(12): 1707–1720.
  16. Braverman NE, Raymond GV, Rizzo WB, et al. Peroxisome biogenesis disorders in the Zellweger spectrum: An overview of current diagnosis, clinical manifestations, and treatment guidelines. Mol Genet Metab. 2016; 117(3): 313–321.
  17. Werner KM, Cox AJ, Qian E, et al. D-bifunctional protein deficiency caused by splicing variants in a neonate with severe peroxisomal dysfunction and persistent hypoglycemia. Am J Med Genet A. 2022; 188(1): 357–363.
  18. Heubi JE, Bove KE, Setchell KDR. Oral cholic acid is efficacious and well tolerated in patients with bile acid synthesis and Zellweger spectrum disorders. J Pediatr Gastroenterol Nutr. 2017; 65(3): 321–326.
  19. Berendse K, Klouwer FCC, Koot BGP, et al. Cholic acid therapy in Zellweger spectrum disorders. J Inherit Metab Dis. 2016; 39(6): 859–868.